DeCode's Q4 Revenues Rise 17 Percent as Loss Grows on Increased R&D Costs | GenomeWeb
NEW YORK (GenomeWeb News) — DeCode Genetics today said fourth-quarter revenues increased 17 percent as R&D spending rose 4 percent and lossed increased 10 percent.
 
Total receipts for the three months ended Dec. 31, 2006, rose to $11.5 million from $9.8 million year over year. DeCode said it has $9.8 million in deferred revenue which will be “recognized over future reporting periods.”
 
R&D spending increased to $14.2 million from $13.7 million year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.